Is Laradatx a funded company?

Laradatx is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Laradatx rank among its competitors?

Laradatx ranks 1514th amongst 1696 active competitors, of which 78 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Laradatx?

Laradatx's top competitors include AbbVie, Amgen and Gilead. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Laradatx - 2026 Company Profile & Competitors

Company Details

Developer of targeted therapies addressing unmet medical needs. The company focuses on creating treatments for conditions where current options are limited or inadequate. It develops pharmaceutical products intended to improve patient outcomes. The organization is involved in research and development activities to advance its therapeutic pipeline.

Key Metrics

Stage

Unfunded

Ranked

1514^th among 1696 active competitors

Similar Companies

AbbVie & 1722 more

View Laradatx's full profile

Laradatx has not raised any funding rounds yet.

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Laradatx include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Laradatx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Menlo Ventures, Jindal ventures & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, 27th Street Capital & 16 others	76/100
6th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	73/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 8 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Gershon Capital, Kaccelerator & 7 others	71/100
9th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100
1514th	Laradatx Unfunded	Developer of targeted therapies addressing unmet medical needs	-	-	16/100